Bergen, Norway, 10 June 2026 - Lifecare ASA (LIFE) today announces successful
completion of the company's first six-month implant evaluation in the
veterinary study, LFC-SEN-002, representing the longest completed in-vivo
assessment of a fully integrated Lifecare implant to date.

The implant that was implanted 9 December 2025, and removed 9 June 2026 in
accordance with study protocol, following six months of continuous
implantation under real-life conditions. The implant remained operational
throughout the implantation period and continued to communicate with external
equipment immediately following explantation.

Initial post-explantation observations demonstrated continued electronic
functionality, no visible mechanical damage to the implant upon microscopic
inspection, and an apparently intact sensor membrane following retrieval.

Importantly, no clinically significant adverse events, foreign body reactions,
or other observable clinical effects beyond the intended monitoring function
were observed during the six-month implantation period.

"This represents one of the most important development milestones achieved by
Lifecare to date," said Joacim Holter, Chief Executive Officer of Lifecare
ASA.

"Long-term functionality and biocompatibility are fundamental requirements for
implantable continuous glucose monitoring. Successfully completing six months
of implantation without observing adverse biological response, while
maintaining system functionality through explantation, provides important
validation of both our implant platform and manufacturing approach."

Real-life use supports individualized diabetes management

Throughout the six-month study period, continuous data was uploaded from the
study system. Together with glucose measurements from reference monitoring
devices and in-clinic blood glucose assessments, this provided the veterinary
team at Norwegian School of Life Sciences (NMBU) with comprehensive data set
for long-term diabetes management. The information supported ongoing clinical
assessment and individualized treatment adjustments throughout the study
period.

Unlike conventional veterinary glucose monitoring approaches, which typically
provide only periodic measurements, the continuous availability of glucose
information allowed closer follow-up of glucose trends and treatment response
over time.

According to both the treating veterinarian and the dog's owners, the
increased access to longitudinal monitoring data contributed to improved
diabetes management and a noticeable improvement in the dog's quality of life
during the study period.

The study has therefore provided not only important information regarding
implant performance, durability and biocompatibility, but also practical
experience demonstrating the potential value of continuous glucose monitoring
in veterinary diabetes care.

Validation of reproducible manufacturing

The implant originated from the first reproducibly manufactured implant batch
established following Lifecare's transition from prototype development toward
reproducible manufacturing processes. Two additional implants manufactured
from the same production batch remain active in the ongoing study and are
progressing toward similar implantation durations.

"We are beginning to establish evidence not only of longevity and
functionality, but of repeatable performance from reproducibly manufactured
implants. This is a critical step in the transition from technology
development toward scalable manufacturing, regulatory execution and
commercialization," Holter continued.

Further analysis underway

The explanted implant will now be transferred for comprehensive laboratory
evaluation, including assessment of sensor performance, chemistry status,
implant condition and tissue response following six months in vivo.

The ongoing longevity program is designed to evaluate long-term implant
performance, durability, biocompatibility and operational stability under
real-life conditions. Results generated through the program continue to
provide important input supporting product development, manufacturing
scale-up, regulatory activities and future commercialization efforts.

Lifecare is currently preparing its next implant production campaign, planned
to commence during July 2026, as part of the company's ongoing transition
toward routine manufacturing operations in Bergen, Norway.

Further updates regarding laboratory analysis and long-term performance
assessments will be communicated when available.

About LFC-SEN-002

LFC-SEN-002 is an ongoing longevity and performance study evaluating
Lifecare's implantable CGM technology in dogs. The study focuses on
biocompatibility, system stability, and in-vivo signal behaviour, and supports
both veterinary product development and future human clinical programs. The
study is conducted under veterinary supervision in cooperation with the
Faculty of Veterinary Medicine, Department of Companion Animal Clinical
Sciences at the Norwegian University of Life Sciences. Data generated in the
study provide direct input to Lifecare's ongoing development and execution
program.

About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring systems to market. Lifecare
enables osmotic pressure as sensing principle. Lifecare's sensor technology is
suitable for identifying and monitoring the occurrence of a wide range of
analytes and molecules in the human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40
Petter Nielsen, CFO, petter.nielsen@lifecare.no, +47 92 24 74 64
on\, please contact:\
\
Joacim Holter\, CEO\, joacim.holter@lifecare.no\, +47 40 05 90 40\
Petter Nielsen\, CFO\, petter.nielsen@lifecare.no\, +47 92 24 74 64\